Bartosz Hudzik: Extended Anticoagulation in Cancer-Associated VTE – Who Is at Higher Bleeding Risk?
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in The Lancet Haematology:
”Extended anticoagulation in cancer-associated VTE: who is at higher bleeding risk?
Extended anticoagulation with reduced-dose apixaban has been shown to be non-inferior to full-dose therapy for preventing recurrent VTE in patients with active cancer—while offering fewer clinically relevant bleeding events.
A new post-hoc analysis of the API-CAT trial takes a closer look at predictors of clinically relevant bleeding during extended therapy.
Key findings (12-month follow-up, n=1,766):
Four factors were independently associated with increased bleeding risk:
• Anaemia and/or thrombocytopenia
• Age ≥75 years
• Pulmonary embolism as the index event
• Male sex
Notably:
• Results were consistent across cancer types
• No interaction with apixaban dose was observed
Why this matters
Although API-CAT was not designed to guide anticoagulation discontinuation, these insights may help clinicians better individualize extended anticoagulation, balancing thrombotic protection against bleeding risk in patients with cancer-associated VTE.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti for the API-CAT Study Group and API-CAT Investigators
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 05:4710-Minute Paper-Strip Test Detects Factor VIII Inhibitors in Resource-Limited Settings – JTH
-
Jun 27, 2026, 05:23New episode – From Groundbreaking Therapies to the Ongoing Fight for Diagnosis – Global Hemophilia Report
-
Jun 27, 2026, 05:08Bethany Brown: Over 400 Ground EMS Agencies Now Carry Lifesaving Blood
-
Jun 27, 2026, 04:56Reza Shojaei: The Plasma Risk Governments Are Ignoring
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management